Why the study?
Thrombolytic treatment accelerates thrombus dissolution in acute pulmonary thromboembolism, but its use in intermediate-risk cases remains controversial, and careful candidate selection is needed to prevent hemorrhage.
Design
Review
Authors
Loading...
PTE response teams may aid intermediate-risk decisions; leaves open outcome impact without prospective validation.
Thrombolytic therapy is a potentially lifesaving treatment for high-risk acute pulmonary thromboembolism, with alteplase being the most widely used agent, though careful patient selection is required to minimize hemorrhage risk.
Elif Yılmazel Uçar (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: